Prostate cancer induction in autoimmune rats and modulation of T cell apoptosis

Journal of Experimental and Clinical Cancer Research

Volumn 18, Issue 4, 1999, Pages 493-504

  Gilardoni, M B ^a   Rabinovich, G A ^a   Oviedo, M ^a   Depiante Depaoli, M ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

Apoptosis; Autoimmunity; Cancer; Prostate

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; TESTOSTERONE PROPIONATE;

ANEUPLOIDY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CANCER IMMUNOLOGY; CONTROLLED STUDY; HISTOPATHOLOGY; IMAGE CYTOMETRY; MALE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATITIS; RAT; T LYMPHOCYTE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; APOPTOSIS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; FLOW CYTOMETRY; HUMANS; MALE; PRECANCEROUS CONDITIONS; PROSTATE; PROSTATIC NEOPLASMS; PROSTATITIS; RATS; RATS, WISTAR; SPLEEN; T-LYMPHOCYTES;

EID: 0033507112     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Pitot H.C., Dragan Y., Xu Y., Peterson J., Hully J. and Campbell, H.: Pathway of carcinogenesis-genetic and epigenetic. In: Harris C.C. ed. Multistage Carcinogenesis. Tokyo Japan Sci. So. Boca Ratón Press: 21-23, 1992.
2. Coffey D.S., Isaacs J.T.: Requirements for an idealized animal model of prostatic cancer. Prog. Clin. Biol. Res. 37: 379-391, 1980.
3. Bosland M.C.: Animal models for the study of prostate carcinogenesis. J. Cell. Biochem. 16: 89-98, 1992.
4. Cairns J.: Mutation selection and the natural history of cancer. Nature (London). 255: 197-200, 1975.
5. Peto R., Roe F.J.C., Lee P.N., Levy L., Clark J.: Cancer and aging in mice and men. Br. J. Cancer 32: 411-426, 1975.
6. Dunning W.F.: Prostate cancer in the rat. Natl. Cancer Inst. Monogr. 12: 351-369, 1963.
7. Pollard M., Luckert P.H.: Transplantable metastasizing adenocarcinomas in rats. J. Natl. Cancer Inst. 54: 643-649, 1975.
8. Pollard M., Luckert P.H.: Production of autochthonous prostate cancer in Lobund-Wistar rats by treatment with N-Nitroso-N-methylurea and testosterone. J. Natl. Cancer Inst. 77: 583-587, 1986.
9. Pollard M., Luckert P.H.: Autochthonous prostate adenocarcinomas in Lobund-Wistar rats: a model system. Prostate 11: 219-227, 1987.
10. Cohen M.B., Heidger P.M., Lubaroff D.M.: Gross and microscopic pathology of induced prostatic complex tumors arising in Lobund-Wistar rats. Cancer Res. 54: 626-628, 1994.
11. Bosland M.C., Prinsen M.K.: Induction of dorsolateral prostate adenocarcinomas and other accessory sex gland lesions in male Wistar rats by a single administration of N-methyl-N-nitrosourea, 7,12-dimethylbenz(α)anthracene, and 3,2′-dimethyll-4-aminobiphenyl after sequential treatment with cyproterone acetate and testosterone propionate. Cancer Res. 50: 691-699, 1990.
12. Bosland M.C., Prinsen M.K., Dirksen T.J.M., Spit B.J.: Characterization of adenocarcinomas of the dorsolateral prostate induced in Wistar rats by N-methyl-N-nitrosourea, 7,12-dimethylbenz(α)anthracene, and 3,2′-dimethyl-4-aminobiphenyl, following sequential treatment with cyproterone acetate and testosterone propionate. Cancer Res. 50: 700-709, 1990.
13. Pollard M.P., Luckert P.H., Schmidt M.A.: Induction of prostate adenocarcinomas in Lobund Wistar rats by testosterone. Prostate 3: 563-568, 1982.
14. Noble R.L.: Prostate carcinoma in the Nb rat in relation to hormones. Int. Rev. Exp. Pathol. 23: 113-159, 1982,
15. Pour P.M., Stepan K.: Induction of prostatic carcinomas and lower urinary tract neoplasms by combined treatment of intact and castrated rats with testosterone propionate and N-nitrosobis (2-oxopropyl)-amine. Cancer Res. 47, 5699-5706, 1987.
16. Bosland M.C., Scherremberg P.M., Ford H., Dreef-van der Meulen H.C.: Promotion by testosterone of N-methyl-N-nitrosourea-induced prostatic carcinogenesis in rats. Proc. Am. Assoc. Cancer Res. 30: 272-277, 1989.
17. Hoover D.M., Best K.L., McKenney B.K., Tamura R.N., Neubauer B.L.: Experimental induction of neoplasia in the accesory sex organs of male Lobund-Wistar rats. Cancer Res. 50: 142-146, 1990.
18. Drago J.R.: The induction of Nb rat prostatic carcinoma. Anticancer Res. 4: 255-256, 1984.
19. Bosland M.C., Han X., Ofner P., Leav I., Liehr J.G.: Induction of DNA adducts and adenocarcinomas in the dorsolateral prostate of NBL rats by combined treatment with estradiol-17β and testosterone. Proc. Am. Assoc. Cancer Res. 33: 277-280, 1992.
20. Pacheco-Rupil B., Depiante-Depaoli M.M., Romero O., Romero M.D., Yantorno C.: Experimental autoimmune damage to rat male accessory glands. Am. J. Reprod. Immunol. 1: 255-261, 1981.
21. Depiante-Depaoli M.M., Pacheco-Rupil B., Britos S., Casas A.: Experimental autoimmune damage to rat male accessory glands. I. Transfer of autoimmune response by spleen cells. Am. J. Reprod. Immunol. 5: 9-11, 1984.
22. Pacheco-Rupil B., Depiante-Depaoli M.M., Casadio B.: Experimental autoimmune damage to rat male accessory glands. II T cell-requirement in adoptive transfer of specific tissue damage. Am. J. Reprod. Immunol. 5, 15-19, 1984.
23. Depiante-Depaoli M.M., Pacheco-Rupil B.: Experimental autoimmune damage to rat male accessory glands (MAG). Circulating antibodies, immunoglobulins bound target glands and immunoglobulin-secreting cells. Am. J. Reprod. Immunol. 7: 32-38, 1987.
24. Depiante-Depaoli M.M., Hliba E., Pacheco-Rupil B.: Experimental autoimmunity against male accessory glands. Correlation between specific tissue damage and reactivity of lymphocytes from thymus, bone marrow, blood, spleen and lymph nodes. Medicina (Bs. As.) 47: 145-153, 1987.
25. Casas-Ingaramo A., Depiante-Depaoli M.M., Pacheco-Rupil B.: Activation of cytotoxic cells by singenic prostate antigens in experimental autoimmune vesiculo-prostatitis. Autoimmunity 9: 151-157, 1991.
26. Orsilles M.A., Donadio A.C., Depiante-Depaoli M.M.: Time course reactive oxygen intermediates release and histopathological findings during experimental autoimmune prostatitis development. Prostate 27: 50-57, 1995.
27. Baretton G.B., Vogt T., Blasenbreu S., Udo L.: Comparison of DNA ploidy in prostatic intraepithelial neoplasia and invasive carcinoma of the prostate: an image cytometry study. Human Pathol. 25: 506-512, 1994.
28. Zier K., Gansbacher B., Salvadori S.: Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol. Today 17: 39-45, 1996.
29. O'Mahony A.M., O'Sullivan G., O'Connell J., Cotter T.G., Collins J.: An immunesuppressive factor derived from esophageal squamous carcinoma induces apoptosis in normal and transformed cells of lymphoid lineage. J. Immunol. 151: 4847-4857, 1993.
30. Hahne M., Rimoldi M., Schröter M., et al.: Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science (Wash. D.C.) 274: 1363-1366, 1996.
31. Deitch A.: Cytophotometry of nucleic acids. In: Weig GL eds. Introduction to quantitative cytochemistry. New York and London Academic Press: 327-354, 1966.
32. Roy A.V., Brower M.E., Hayden J.E.: Sodium thymolphtalein monophosphate: a new acid phosphatase substrate with greater specificity for the prostatic enzyme in serum. Clin. Chem. 17: 1093-1102, 1971.
33. Orlowski J., Bird C.E., Clark A.F.: Androgen metabolism and regulation of rat ventral prostate growth acid phosphatase during sexual maturation. J. Endocrinol. 116: 81-90, 1988.
34. Gendimenico G.J., Bouquin P.L., Tramposch K.M.: Diphenilamine-colorimetric method for DNA assay: a shortened procedure by incubating samples at 50°C. Anal. Biochem. 173: 45-49, 1988.
35. Rabinovich G.A., Modesti N.M., Castagna L.F., Landa C.A., Riera C.M., Sotomayor C.E. Specific inhibition of lymphocyte proliferation and induction of apoptosis by CLL-I, a β-galactoside-binding lectin. J. Biochem. (Tokyo). 122: 365-373, 1997.
36. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., Riccardi C.: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139: 271-279, 1991.
37. Haggman M.J., Macoska J.A., Wojno K.J., Oesterling J.E.:. The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J. Urol. 158: 12-22, 1997.
38. Pollard M.: Spontaneous prostate adenocarcinomas in aged germfree Wistar rats. J. Natl. Cancer Inst. 51: 1235-1241, 1973.
39. Younus J., Ahmed A.R.: Autoimmunity and malignancy. J. Am. Acad. Dermatol. 23: 720-723, 1990.
40. Wodzig K.W., Beijleveld L.J., Damoiseaux J.G., Arends J.W., van Breda Vriesman P.J.: Malignant neoplasms in cyclosporin-A-induced autoimmunity (CyA-AI). Int. J. Cancer 72: 530-535, 1997.
41. Fernandez-Madrid F., Karvonen R.L., Kraut M.J., Czelusniak B., Ager J.W.: Autoimmunity to collagen in human lung cancer. Cancer Res. 56: 121-126, 1996.
42. Liu K-J, Chatta G.S., Twardzik D.R., et al.: Identification of rat steroid-binding protein as a target antigen of experimental autoimmune prostatitis. Implications for prostate cancer therapy. J. Immunol. 59: 472-480, 1997.
43. Ottenhoff T.H.: Selective modulation of T-cell responses in autoimmunity and cancer. Immunol. Today 17: 54-55, 1996.
44. Nagata S., Goldstein P.: The Fas death factor. Science (Wash. DC). 26: 1449-56, 1995.
45. Osborne B.A.: Apoptosis and the maintenance of homeostasis in the immune system. Curr. Opin. Immunol. 8: 245-250, 1996.
46. O'Connell J., Bennett MW., O'Sullivan G.C., Collins J.K., Shanahan F.: The Fas counterattack: cancer as a site of immune privilege. Immunol. Today 20: 46-52, 1999.
47. Kayagaki N., Kawasaki A., Ebata T., et al.: Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182: 1777-1783. 1995.
48. Tanaka M., Suda T., Takahashi T., Nagata S.: Expression of the function soluble form of human Fas ligand in activated lymphocytes. EMBO J. 14: 1129-1135, 1995.
49. Mizutani Y., Yoshida O., Bonavida B.: Prognostic significance of soluble Fas in the serum of patients with bladder cancer. J. Urol. 160: 571-576, 1998.